Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer ; day:15 ; month:4 ; year:2020 ; pages:1-4
Magazine of European Medical Oncology ; (15.4.2020), 1-4
- Urheber
-
Marhold, Maximilian
Topakian, Thaïs
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-020-00599-9
- URN
-
urn:nbn:de:101:1-2020062813411675720150
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Marhold, Maximilian
- Topakian, Thaïs
- SpringerLink (Online service)
Ähnliche Objekte (12)
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
PARP‐1 regulates DNA repair factor availability
A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
PARP‐1 regulates DNA repair factor availability
A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
PARP‐1 regulates DNA repair factor availability
A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition